News for Stoke Therapeutics, Inc. (STOK)

Quarterly Revenue: $22.6 million, significantly surpassing the estimated $4.28 million.Quarterly EPS: Reported at -$0.18, outperforming the estimated -$0.53.Ca

[url=

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 64.71% and 483.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

[url=

Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

[url=

Biogen & Stoke team up to advance zorevunersen for Dravet syndrome globally

Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fou

Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline and market-expanding potential.

On December 31, 2024, Lynx1 Capital Management LP (Trades, Portfolio) made a significant move by acquiring an additional 4,672,349 shares of Allogene Therapeuti

Overview of the Recent Transaction On December 31, 2024, Lynx1 Capital Management LP (Trades, Portfolio) executed a notable transaction by acquiring 766,051 sha

Significant Transaction in Stoke Therapeutics Inc On December 31, 2024, RTW INVESTMENTS, LP (Trades, Portfolio) executed a notable transaction by acquiring an a

Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.

[url=

On December 27, 2024, Lynx1 Capital Management LP (Trades, Portfolio) made a significant move by acquiring an additional 373,645 shares of Passage Bio Inc (PASG

On December 23, 2024, Skorpios Trust (Trades, Portfolio) executed a significant transaction involving Stoke Therapeutics Inc (NASDAQ: STOK). The firm reduced it

ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.